Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml
Synlett 2020; 31(02): 165-170
DOI: 10.1055/s-0037-1610738
DOI: 10.1055/s-0037-1610738
letter
Synthesis and Biological Activity of 4-(Pyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic Acid Derivatives
This work was performed with financial support from the Committee for Sciences, Ministry of Education and Science of the Republic of Kazakhstan (Grant No. AP05131602) and RFBR according to the research project No. 19-03-00376.Further Information
Publication History
Received: 29 September 2019
Accepted after revision: 17 November 2019
Publication Date:
29 November 2019 (online)
![](https://www.thieme-connect.de/media/synlett/202002/lookinside/thumbnails/st-2019-b0517-l_10-1055_s-0037-1610738-1.jpg)
Abstract
Claisen condensation reaction of diethyl oxalate with 1-[4-(furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]ethan-1-one afforded (Z)-4-[4-(furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]-2-hydroxy-4-oxobut-2-enoic acid. The latter reacted with various binucleophiles to form the corresponding 3,4-dihydroquinoxaline-2(1H)-one, 3,4-dihydro-2H-benzo[b][1,4]oxazin-2-one, and 1H-pyrazole derivatives. Biological screening of the obtained compounds revealed analgesic and antibacterial activity.
Key words
α,γ-diketo acids - 3,4-dihydroquinoxalin-2(1H)-ones - 3,4-dihydro-2H-benzo[b][1,4]oxazin-2-ones - 1H-pyrazoles - analgesic activity - antibacterial activitySupporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1610738.
- Supporting Information
-
References and Notes
- 1 Mashkovsky MD. Medicines (in Russian). New Wave; Moscow: 2017: 1216
- 2 Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK. Bioorg. Med. Chem. 2007; 15: 1212
- 3 Di Santo R, Costi R, Roux A, Miele G, Crucitti GC, Iacovo A, Rosi F, Lavecchia A, Marinelli L, Di Giovanni C, Novellino E, Palmisano L, Andreotti M, Amici R, Galluzzo CM, Nencioni L, Palamara AT, Pommier Y, Marchand C. J. Med. Chem. 2008; 51: 4744
- 4 Nair V, Okello M. Molecules 2015; 20: 12623
- 5 Pommier Y, Johnson AA, Marchand C. Bioorg. Med. Chem. Lett. 2009; 19: 222
- 6 Sidique S, Ardecky R, Su Y, Narisawa S, Brown B, Millan JL, Sergienko E, Cosford ND. Bioorg. Med. Chem. Lett. 2009; 19: 222
- 7 El-Hawash SA. M, Soliman R, Youssef AM, Ragab HM. A, Elzahhar PA. S, El-Ashmawey IM, Abdel Wahab AE, Shaat IA. Med. Chem. 2014; 10: 318
- 8 Roman R, Navarro A, Wodka D, Alvim-Gaston M, Husain S, Franklin N, Simón-Fuentes A, Fustero S. Org. Process Res. Dev. 2014; 18: 1027
- 9 Shehab WS, El-Bassyouni GT. J. Iran. Chem. Soc. 2018; 15: 1639
- 10 Singh DP, Deivedi SK, Singhal RG. Pharmaceuticals 2010; 3: 2416
- 11 Zarranz B, Jaso A, Aldana I, Monge A. Bioorg. Med. Chem. Lett. 2003; 11: 2149
- 12 Pereira JA, Pessoa AM. Eur. J. Med. Chem. 2015; 97: 664
- 13 Ramalingam P, Ganapaty S, Rao CB. Bioorg. Med. Chem. Lett. 2010; 20: 406
- 14 Petronijević J, Janković N, Stanojković TP, Joksimović N, Grozdanić N. Đ, Vraneš M, Tot A, Bugarčić Z. Arch. Pharm. 2018; 351: 1700308
- 15 Petronijević J, Bugarčić Z, Bogdanović GA, Stefanović S, Janković N. Green Chem. 2017; 19: 707
- 16 Gein VL, Rassudikhina NA, Shepelina NV, Vakhrin MI, Babushkina EB, Voronina EV. Pharm. Chem. J. 2008; 42: 529
- 17 Kulakov IV, Karbainova AA, Shulgau ZT, Seilkhanov TM, Gatilov YV, Fisyuk AS. Chem. Heterocycl. Compd. 2017; 53: 1094
- 18 Sagitullina GP, Glizdinskaya LV, Sagitullin RS. Chem. Heterocycl. Compd. 2005; 41: 739
- 19 Koveza VA, Kulakov IV, Shulgau ZT, Seilkhanov TM. Chem. Heterocycl. Compd. 2018; 54: 1127
- 20 (Z)-4-[4-(Furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]-2-hydroxy-4-oxobut-2-enoic Acid (4) To a freshly prepared sodium n-butoxide, prepared from sodium metal (920 mg, 4.0 mmol) dissolved in anhydrous n-BuOH (0.9 mL), was added diethyl oxalate (730 mg, 5.0 mmol) in anhydrous Et2O (30 mL). To this mixture was added with stirring a solution of 1-[4-(furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]ethan-1-one (3, 1.0 g, 3.0 mmol) in anhydrous benzene (2 mL). The reaction mixture was reflux for 6 h. The formed yellow precipitate of diketo ester salt was filtered and dissolved in 0.03 N NaOH (250 mL). The mixture was vigorously stirred for 3 h at room temperature, then was acidified with concentrated HCl (to pH 3–4). The resulting precipitate was filtered, washed with water, and air-dried. Recrystallization from mixture of 2-propanol–water (3:1) afforded the light brown crystals; yield 970 mg (82%); mp 120–122 °С. IR: νmax = 3559 (OH), 1719 (C=O), 1538, 1354 (NO2) cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.71 (s, 3 H, –CH3), 6.35 (s, 1 H, =CH), 6.53 (d, J = 5.0 Hz, 1 H, H-4′ Fur), 6.78 (d, J = 3.1 Hz, 1 H, H-3′ Fur), 7.49–7.52 (m, 3 H, H-3′,4′,5′ Ph), 7.56 (br s, 1 H, H-5′ Fur), 7.62–7.64 (m, 2 H, H-2′,6′ Ph) ppm. 13C NMR (101 MHz, CDCl3): δ = 23.36 (–CH3), 103.50, 112.79, 115.10, 128.04, 128.93, 129.46, 130.39, 134.87, 142.34, 142.91, 145.88, 151.61, 157.14, 162.61, 166.88 (COOH), 194.07 (C=O) ppm. Anal. Calcd for C20H14N2O7: C, 60.92; H, 3.58; N, 7.10; O, 28.40. Found: C, 60.61; H, 3.32; N, 7.01; O, 28.11.
- 21 X-ray Structural Study X-ray structural study was performed at room temperature on a CCD diffractometer ‘Xcalibur, Oxford Diffraction’. The structure was solved by direct method and refined anisotropically with full-matrix method of least squares by all reflections using the SHELXL software suite. The hydrogen atom positions were calculated geometrically and refined according to the ‘rider’ model. The positions of hydrogen atoms belonging to hydroxyl groups were refined isotropically. The crystals of compound 4 (C20H14N2O7, M 394.34) were monoclinic, space group P21/c; a = 11.4931(3), b = 10.3438(2), c = 17.2566(4) Å; V = 1947.74(8) Å3; Z = 4; d calcd = 1.406 g/cm3. A total of 33424 reflections were collected (θ max 76.145°), including 4040 independent, R int = 0.0476. The final values of probability factors were R = 0.0417 (for 3243 reflections with I > 2σ(I)), wR = 0.1155, S = 1.022 for all reflections. The complete crystallographic dataset was submitted to the Cambridge Crystallographic Data Center (deposit CCDC 1935337).
- 22 (Z)-3-{2-[4-(Furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]-2-oxoethylidene}-3,4-dihydroquinoxalin-2(1H)-one (5a) A mixture both of compound 4 (200 mg, 0.5 mmol) and o-phenylenediamine (1 equiv, 54 mg, 0.5 mmol) in 2-propanol (2 mL) was stirred for 3 h at 60–80°C and then left to cool. The formed yellow precipitate was filtered, washed with 2-propanol, and air-dried. The crude product was purified by recrystallized from a mixture of 2-propanol–dichloromethane (5:1); yield 210 mg (90%); bright-yellow crystals; mp 258–260 °C. IR: νmax = 1677–1611 (C=O), 1536, 1374 (NO2) cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.70 (s, 3 H, –CH3), 6.23 (s, 1 H, =CH), 6.43 (br s, 1 H, H-4′ Fur), 6.76 (d, J = 3.05 Hz, 1 H, H-3′ Fur), 7.12 (d, J = 7.63 Hz, 1 H, H-5′′ Ar), 7.21 (dd, J = 14.5 Hz, 8.39 Hz, 2 H, H-6′′,7′′ Ar), 7.30 (d, J = 7.60 Hz, 1 H, H-8′′ Ar), 7.48 (br s, 4 H, H-3′,4′,5′ Ph, H-5′ Fur), 7.61–7.63 (m, 2 H, H-2′,6′ Ph), 10.50 (s, 1 H, CONH), 13.48 (s, 1 H, NH) ppm. 13C NMR (101 MHz, CDCl3): δ = 23.32 (–CH3), 95.02, 112.25, 114.51, 115.92, 116.53, 124.21, 125.08, 128.03, 128.82, 129.91, 133.43, 142.49, 143.96, 145.02, 145.26, 150.36, 156.72, 192.79 (C=O) ppm. Anal. Calcd for C26H18N4O5: C, 66.95; H, 3.89; N, 12.01; O, 17.15. Found: C, 66.75; H, 3.64; N, 12.33; O, 17.29.
- 23 (Z)-3-{2-[4-(Furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]-2-oxoethylidene}-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-one (5b) Compound 5b was obtained from compound 4 (160 mg, 0.4 mmol) and o-aminophenol (1 equiv, 44 mg, 0.4 mmol) analogously to the procedure for preparation of compound 5a; yield 150 mg (78%); bright-yellow crystals; mp 216–218 °С. IR: νmax = 1761–1624 (C=O), 1561, 1351 (NO2) cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.69 (s, 3 H, –CH3), 6.23 (s, 1 H, =CH), 6.48 (br s, 1 H, H-4′ Fur), 6.75 (d, J = 3.05 Hz, 1 H, H-3′ Fur), 7.20–7.27 (m, 4 H, H-5′′,6′′,7′′,8′′ Ar), 7.50 (br s, 4 H, H-3′,4′,5′ Ph, H-5′ Fur), 7.62–7.64 (m, 2 H, H-2′,6′ Ph), 12.75 (s, 1 H, NH) ppm. 13C NMR (101 MHz, CDCl3): δ = 23.31 (–CH3), 98.30, 112.40, 114.59, 116.20, 117.26, 122.96, 124.81, 125.98, 128.00, 128.82, 130.00, 132.77, 135.36, 139.13, 141.39, 142.45, 143.58, 145.43, 150.61, 155.13, 156.71, 194.11 (C=O) ppm. Anal. Calcd for C26H17N3O6: C, 66.81; H, 3.67; N, 8.99; O, 20.54. Found: C, 66.98; H, 3.87; N, 8.73; O, 20.31
- 24 (Z)-3-{2-[4-(furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]-2-oxoethylidene}-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-one (5c) Yield 160 mg (80%); bright-yellow crystals; mp 290–292 °C. IR: νmax = 1771 (C=O), 1575, 1340 (NO2) cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.69 (s, 3 H, –CH3), 6.31 (s, 1 H, =CH), 6.51 (br s, 1 H, H-4′ Fur), 6.77 (d, J = 3.10 Hz, 1 H, H-3′ Fur), 7.28–7.30 (m, 1 H, H-5′′ Ar), 7.51–7.52 (m, 4 H, H-3′,4′,5′ Ph, H-5′ Fur), 7.62–7.64 (m, 2 H, H-2′,6′ Ph), 8.13 (s, 1 H, H-8′′ Ar), 8.18 (d, J = 6.10 Hz, 1 H, H-6′′ Ar), 12.59 (s, 1 H, NH) ppm. 13C NMR (101 MHz, DMSO-d 6): δ = 23.31 (–CH3), 98.30, 112.40, 114.59, 116.20, 117.26, 122.96, 124.81, 125.98, 128.00, 128.82, 129.24, 130.00, 132.77, 135.36, 139.13, 141.39, 142.45, 143.58, 145.43, 150.61, 155.13, 156.71, 194.11 (C=O) ppm. Anal. Calcd for C26H16N4O8: C, 60.94; H, 3.15; N, 10.93; O, 24.98. Found: C, 60.65; H, 3.39; N, 10.74; O, 24.76
- 25 Synthesis of 1H-Pyrazole-3-carboxylic Acids 6a,b – General Method To a solution of compound 4 (200 mg, 0.5 mmol) in ethanol (2 mL) was added with stirring of the corresponding hydrazine (4 equiv). The reaction mixture was stirred for 3 h at 50–60 °C and then left to cool. The formed precipitate was filtered, washed with ethanol, and air-dried. Recrystallization from ethanol afforded the pyrazole derivatives 6a,b.
- 26 5-[4-(Furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]-1H-pyrazole-3-carboxylic Acid (6a) Yield 174 mg (89%); light-yellow crystals; mp 212–215 °С. IR: νmax = 3356,2 (OH), 3166,2 (N–H), 1656 (C=O), 1531, 1340 (NO2) cm–1. 1H NMR (400 MHz, DMSO-d 6): δ = 2.43 (s, 3 H, –CH3), 6.05 (d, J = 4.58 Hz, 1 H, H-4′ Fur), 6.36 (br s, 1 H, H-3′ Fur), 6.50 (s, 1 H, H-4 pyrazole), 7.53–7.55 (m, 6 H, H-2′,3′,4′,5′,6′ Ph, H-5′ Fur), 7.77 (1 H, s, NH) ppm. 13C NMR (101 MHz, DMSO-d 6): δ = 23.93 (–CH3), 106.49, 112.16, 114.57, 127.81, 128.76, 129.79, 130.67, 135.69, 142.41, 143.60, 144.45, 145.46, 149.05, 160.55, 163.26 (–COOH) ppm. Anal. Calcd (%) for C20H14N4O5: C, 61.54; H, 3.62; N, 14.35; O, 20.49. Found (%): C, 61.77; H, 3.85; N, 14.71; O, 20.78.
- 27 5-[4-(Furan-2-yl)-2-methyl-5-nitro-6-phenylpyridin-3-yl]-1-phenyl-1H-pyrazole-3-carboxylic Acid (6b) Yield 175 mg (75%); light-yellow crystals; mp 215–217 °С. IR: νmax = 1709 (C=O), 1536, 1368 (NO2) cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.47 (s, 3 H, –CH3), 6.17 (d, J = 4.60 Hz, 1 H, H-4′ Fur), 6.40 (br s, 1 H, H-3′ Fur), 7.06 (s, 1 H, H-4 pyrazole), 7.15 (d, J = 7.63 Hz, 2 H, H-2′′,6′′ Ph), 7.29–7.37 (m, 4 H, H-4′ Ph, H-3′′,4′′,5′′ Ph), 7.45–7.51 (m, 3 H, H-3′,5′ Ph, H-5′ Fur), 7.62 (d, J = 7.70 Hz, 2 H, H-2′,6′ Ph) ppm. 13C NMR (101 MHz, CDCl3): δ = 24.32 (–CH3), 77.31, 77.63, 112.51, 112.71, 114.83, 121.88, 124.15, 128.28, 129.16, 129.29, 129.49, 130.55, 132.37, 135.41, 138.54, 139.53, 142.99, 143.86, 144.02, 145.59, 160.29, 165.82 (–COOH) ppm. Anal. Calcd for C26H18N4O5: C, 66.95; H, 3.89; N, 12.01; O, 17.15. Found: C, 66.79; H, 3.71; N, 12.25; O, 17.27.
- 28 The Study of Analgesic Activity The study was performed on mice by recording the specific pain reaction of writhing (characteristic movements of animals, including contractions of abdominal musculature alternating with relaxation, extension of hind limbs, and arching of back), caused by intraperitoneal injection of 0.75% acetic acid (0.1 mL per 10 g of body weight). The number of writhings for each animal was counted during the subsequent 15 min (using groups of 5 animals). The analgesic effect was determined from the decrease in number of writhings, expressed as percentage relative to the control. The studied compounds were introduced in the amount of 100 mg/kg body weight as a suspension in drinking water into the stomach by using a feeding tube at 30 min prior to the intraperitoneal injection of acetic acid. The reference drug was metamizole sodium (analgin), which was introduced by analogous scheme in the amount of 100 mg/kg body weight. The control animals received analogous volume of drinking water.30,31
- 29 The Study of Antibacterial Activity Samples of the studied chemicals were diluted in 1 mL of DMSO (Sigma). After which a series of twofold dilutions in DMSO were prepared. Determination of the minimum inhibitory concentration (MIC) was carried out by conventional broth microdilution methods based on the Clinical and Laboratory Standards Institute (CLSI). The overnight cultures of the Gram-positive S. aureus FDA 209 P and Gram-negative E. coli K12 test strains were diluted in LB- broth (Sigma-Aldrich, USA) in order to obtain 106 CFU/mL. Prepared inoculums were mixed with twofold dilutions of chemicals and incubated for 24 h in 96-wells microtiter plate (Costar 3595, Corning corp, USA). After incubation, the optical density of planktonic cells was assessed by reading the absorbance data at 620 nm using spectrophotometer Multiscan GO (Thermo Scientific). Antimicrobial activity of chemicals was indicated by the minimal inhibitory concentration, which was defined as the lowest dose at which no visible growth was detected. Determination of bactericidal activity was performed by plating of the treated bacteria from the wells on LB-agar (Sigma-Aldrich, USA). Following incubation, CFU counting was conducted.32
- 30 Mironov AN, Bunatyan ND, Vasiljev AN, Verstakova OL, Zhuravleva MV, Lepakhin VK, Korobov NV, Merkulov VA, Orekhov SN, Sakaeva IV, Uteshev DB, Yavorsky AN. Guidelines for Conducting Preclinical Studies of Drugs (in Russian), Vol. 1. Griff and K; Moscow: 2012: 746
- 31 All experimental work with laboratory animals was performed according to the generally accepted bioethics principles for work involving laboratory animals, in accordance with the European Convention for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes (ETS 123); Strasbourg, 1986.
- 32 Mironov AN, Bunatyan ND, Vasiljev AN, Verstakova OL, Zhuravleva MV, Lepakhin VK, Korobov NV, Merkulov VA, Orekhov SN, Sakaeva IV, Uteshev DB, Yavorsky AN. Guidelines for Conducting Preclinical Studies of Drugs (in Russian), Vol. 1. Griff and K; Moscow: 2012: 509